Fresenius Medical Care AG & Co. KGaA (FMS) Expected to Announce Earnings on Tuesday

Key Points

• Fresenius Medical Care is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast earnings of $0.651 per share and revenue of $5.54 billion, with an earnings call scheduled for 8:00 a.m. ET.
• The company exceeded expectations in its prior quarter, reporting $0.66 EPS versus a $0.62 consensus estimate and $5.55 billion in revenue compared with $5.48 billion expected.
• Analyst sentiment remains cautious: seven analysts rate the stock Hold and four rate it Sell, resulting in a consensus “Reduce” rating and a $23.42 target price. Shares recently opened at $22.75.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.6510 per share and revenue of $5.54 billion for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2.24 EPS for the current fiscal year and $2.31 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS opened at $22.75 on Tuesday. The company has a 50-day simple moving average of $22.48 and a 200-day simple moving average of $22.89. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $27.40. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of 11.78, a PEG ratio of 5.29 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on FMS shares. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong sell" rating in a research note on Thursday, October 15th. Berenberg Bank set a $24.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Citigroup restated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Finally, Sanford C. Bernstein increased their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.